Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
A new AR system using HoloLens enables doctors to perform transperineal prostate interventions with high accuracy and flexibility. The system provides a 3D immersive experience, allowing doctors to guide needles to their target with ease.
Researchers analyzed zika virus effects on tumor cells and healthy cells, discovering its potential to treat prostate cancer but also triggering a persistent inflammatory process that damages the male reproductive system. The study's findings suggest long-term treatment could lead to recurrence of prostate cancer.
A team led by Abhinav Jha is developing a novel low-count quantitative single photon emission computed tomography (LC-QSPECT) method to measure the concentration of radiopharmaceutical material in tumors and vital organs. This technique aims to provide accurate measurements of absorbed dose from radiation therapy, helping plan treatmen...
Researchers characterized prostate cancer cell dynamics at single-cell resolution, revealing an expansion of intermediate cells that correlates with treatment resistance and poor clinical outcomes. A 5-gene signature associated with treatment resistance was also discovered.
A new diagnostic pathway for prostate cancer reduces the number of harmless tumors found during screening, halving the risk of overdiagnosis. This strategy involves using MRI to guide targeted tissue sampling, reducing the need for unnecessary biopsies and associated complications.
Researchers analyzed genetic data from 233 patients with ovarian cancer and found that precise localization of BRCA gene mutations is crucial for effective treatment. The study suggests that PARP inhibitors can be highly effective in patients with mutations in the DNA-binding domain, leading to improved overall survival rates.
Research emphasizes the importance of ethnically diverse prostate cancer genomics data and accessible genetic testing. Variations in genomic landscape of prostate cancer were observed in Chinese men compared to Western cohorts, with lower mutation rates in driver genes such as TP53 and PTEN.
A novel radiopharmaceutical treatment targeting prostate-specific membrane antigen effectively shrinks prostate tumors in mice, with minimal impact on major organs. Researchers plan to launch a clinical trial for refractory prostate cancer patients in two years.
A small clinical trial showed 40% of patients experienced progression-free survival when treated with a CD105 inhibitor, which prevented cancer cells from making splice variant proteins. This approach may resensitize select patients to androgen suppression therapy.
A new study finds that combining radiation with hormone therapy can improve outcomes for patients with oligometastatic prostate cancer. The trial showed that patients who received both treatments experienced longer progression-free survival and better testosterone levels after treatment.
A study from the University of Gothenburg found that the number of surgeries performed by a urology surgeon has no effect on men's risk of developing postoperative urinary incontinence after prostate cancer surgery. The researchers analyzed data from over 4,600 men who underwent robot-assisted radical prostatectomy between 2017 and 2019.
Men with early prostate cancer are missing opportunities for detection because national guidelines and media health campaigns focus on urinary symptoms despite a lack of scientific evidence. Prostate cancer can be a silent or asymptomatic disease, particularly in its curable stages.
The Tango assay combines accumulation and a logical AND gate operation to identify prostate cancer biomarkers in blood samples. It achieves 91% accuracy in detecting prostate cancer in just 15 minutes, offering a non-invasive alternative to biopsies.
SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateJul 20, 2022
A proteomic study of 2,002 tumors identified 11 distinct molecular subtypes across 14 tissue-based cancer types, including breast, lung, and brain cancers. These subtypes provide new insights into the deregulated pathways and processes in tumors that make them cancerous.
A study by Cedars-Sinai researchers confirms that counting metastatic lymph nodes is a dominant predictor of cancer death, improving staging and treatment for solid tumors. The simple process can be applied in virtually all medical settings without increased cost or complexity.
Experts advise against routine prostate cancer tests for asymptomatic men due to the test's limited ability to prevent deaths and potential for overdiagnosis. Instead, they recommend using a 'risk checker' tool to explore options with a doctor, emphasizing the need for evidence-based guidance on PSA testing.
The ECOG-ACRIN Cancer Research Group presented promising trial results at ASCO 2022, including an 8-year survival rate in the CHAARTED prostate trial. The research also explored outcomes by tobacco use in head and neck studies, shedding light on cancer treatment effectiveness.
Researchers at Weill Cornell Medicine found that tumors recruit nearby cells called fibroblasts to work as their enablers by releasing lactate. This finding suggests that future drug treatments could target this defense mechanism to help cancer patients.
A large population study found that smoking increases the risk of dying from prostate cancer, regardless of tumor stage, and is associated with a poorer prognosis. Smokers have a lower risk of developing prostate cancer but are more likely to be diagnosed at an advanced stage.
A new study by Weill Cornell Medicine investigators found that T cells' genetic program and developmental path affect their response to immunotherapy. The results suggest that infiltrating T cells don't all meet the same fate in every tumor, with long-lived memory programs correlating strongly with overall survival
A novel nuclear medicine combination therapy combining <sup> 177 </sup> Lu-PSMA-617 with idronoxil (NOX66) has been shown to be safe and effective in reducing PSA levels by over 50% in men with metastatic prostate cancer. The median overall survival was 19.7 months, suggesting potential for improved patient outcomes.
Levi A. Garraway is being honored for his groundbreaking contributions to cancer research, including the identification of melanoma genes and development of precision oncology approaches. He has also championed parallel sequencing as a definitive approach to tumor genomic profiling, revolutionizing cancer treatment strategies.
Researchers at Massachusetts General Hospital have found that cancer cells expressing certain kinases are more responsive to targeted therapies. These findings may help tailor treatments to individual patients based on the specific types and levels of protein expression in their tumors.
Scientists at University College London have developed a novel cancer therapy using magnetic seeds guided by an MRI scanner to heat and destroy tumours. The therapy, called MINIMA, has the potential to precisely treat hard-to-reach cancers with minimal side effects.
A meta-analysis published in The Lancet Oncology reveals that men with intermediate- and high-risk prostate cancer experience improved overall survival with the addition of hormone therapy to radiotherapy. The study found prolonged adjuvant hormone therapy benefits men, while neoadjuvant hormone therapy did not.
Researchers have identified NDUFS1 and ATP5O as novel markers of aggressive prostate cancer, associated with poorer survival rates. The study's findings provide new insights into the disease's molecular mechanisms and potential targets for therapy.
Surgeons at Henry Ford Health performed the world's first precision prostatectomy through the bladder using a single port robotic surgical system. The procedure preserves a portion of the prostate capsule, improving functional outcomes such as erectile function and urinary control.
Researchers have developed a prostate cancer organoid that can mimic the patient-specific microenvironment, opening up new avenues for targeted treatments. The study reveals that extracellular matrix regulates EZH2 activity and efficacy of inhibitors, as well as identifies potential new therapeutic targets like DRD2.
Researchers have developed a new approach to studying prostate cancer, allowing them to track the behavior of individual cancer cells from birth to organ spread. The technique uses whole-organ imaging and artificial intelligence to create a 3D reconstruction of the organ at single-cell resolution.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
A new pilot study reveals a prostate cancer urine test can identify men with intermediate-risk disease, allowing them to opt for active surveillance instead of immediate treatment. The test assesses the amount of aggressive cancer in the prostate without needing a biopsy.
A study analyzing 6,775 patients with low-risk prostate cancer found that cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment. The study also found that higher Gleason grade, PSA level, tumor stage, and number of positive biopsy cores are related to shorter conversion times.
A novel blood test, Stockholm3, can reduce the number of MRIs performed by a third while preventing the detection of minor, low-risk tumours. The addition of this test to MRI reduces overdiagnosis by as much as 69% and halves the number of biopsies.
Researchers have found a way to harness the power of immunotherapy for advanced prostate cancer by targeting a protein called PIKfyve. Blocking PIKfyve with the inhibitor ESK981 has been shown to increase tumor death and recruit immune T cells, offering new hope for patients with this challenging form of cancer.
Researchers identified a subset of localized prostate cancers that exhibit characteristics typical of 'hot' tumors, which may respond to immunotherapies. The study found that about a quarter of high-risk prostate cancers have these immunologic traits, suggesting a substantial number of patients may benefit from immunotherapy.
Researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer. Inhibiting the protein H6PD leads to significantly reduced tumor sizes and improved survival among mouse models with drug-resistant prostate cancer.
A new approach uses T cell engineering to deliver the gene coding for IL-24, which targets cancer cells regardless of their expression of target molecules. This method blocks tumor growth, starves tumors of nutrients, and generates memory T cells that can theoretically kill tumors if they recur.
Tumor gene profiling decreases patient acceptance of active surveillance among men with clinically similar prostate cancers and low health literacy, a new study found. The study suggests that education on prostate cancer treatment options is needed for this population.
A new study found that a high rate of genetic mutations within a tumor (high tumor mutation burden) can predict clinical responses to immune checkpoint inhibitors in certain cancer types, such as melanoma, lung and bladder cancer. However, this was not the case for other cancers, including breast, prostate and brain cancers.
Researchers at the University of Bern developed a new strategy to assess therapy response in prostate cancer patients. They created patient-derived organoids that retain relevant characteristics of the original tumors, allowing for targeted drug testing and potential treatment repurposing.
A study by researchers at UCLA Jonsson Comprehensive Cancer Center found that MRI frequently underestimates the size of prostate tumors, which can lead to undertreatment. The accuracy of treatment depends on precise measurements of both tumor size and PI-RADS score.
A clinical trial combining microbubbles with radiation therapy has shown promising results in treating liver cancer. The treatment increased tumor response rates by 93% compared to standard radiation alone, and improved patient outcomes, including longer overall survival and reduced need for retreatments.
Researchers at Memorial Sloan Kettering Cancer Center found that tumors with high mutation burden, particularly those with BRCA2 mutations, respond better to immunotherapy. This discovery may lead to more precise treatments for patients with BRCA2 mutations.
Research reveals that African American men's prostate cancer tumors have higher frequencies of certain genetic alterations compared to white men. These alterations may contribute to more aggressive disease and higher mortality rates among Black men.
Researchers at UT Southwestern Medical Center have discovered two experimental drugs that can suppress the growth and spread of non-small cell lung cancer (NSCLC) by affecting its blood vessels, oxygen levels, and other environmental factors. The findings highlight the potential of these drugs for NSCLC treatment.
Researchers developed a simplified process to estimate radiation dose using a single post-treatment SPECT/CT scan, potentially improving therapeutic outcomes by tailoring treatments to individual patients' physiology. The method was applied to 177Lu-PSMA-617 therapy for metastatic prostate cancer.
Researchers found the AZIN1 gene associated with metastatic prostate cancer, with reduced expression leading to fewer metastases. Further investigation is needed to confirm findings in all prostate cancers.
Targeted radionuclide therapy has been shown to improve the effectiveness of immunotherapies in treating prostate cancer by modifying the tumor microenvironment. The treatment can achieve immunomodulation at relatively low radiation doses without affecting the normal immune system.
Researchers identified four subtypes of prostate cancer with distinct characteristics, affecting treatment strategies and potentially improving patient outcomes. The study's findings suggest that one subtype requires intensified treatments while another is less aggressive, paving the way for more targeted therapies.
A new mathematical model predicts prostate cancer tumor growth and invasiveness based on stromal ecology, revealing that highly reactive stroma drives aggressive tumors. The model was validated in animal models and patients, suggesting improved prognosis with ecological metrics.
A clinical trial has identified a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment. The study found that these tumors had lower androgen receptor activity and higher stemness, making them more adaptable and resistant to treatment.
Researchers have developed a unique immunotherapy delivery system that can turn cold tumors into 'hot' tumors, making it effective in cancers such as breast and melanoma. The system uses a protein called interleukin 12 to inflame the tumor and activate the immune system.
The iPS87 cell line is characterized as a cancer-inducing, stem cell-like cell line that can be used to develop novel treatments for prostate cancer. After 8 transfers, the cultured cells lost their tumor-inducing capability and stem cell marker expression.
The study found that SRK-181 inhibits latent TGFβ1 activation with high selectivity and overcomes primary resistance to checkpoint blockade therapy by altering the tumor immune landscape. Preclinical results demonstrated improved preclinical safety profiles compared to conventional inhibitors of TGFβ signaling.
Researchers in Brazil identified a gene expression profile associated with cachexia, a potentially fatal syndrome characterized by severe weight loss and muscle wasting. The study found that pancreatic, esophageal, colorectal, stomach, and head-and-neck cancers are most frequently linked to cachexia.
Researchers identified novel PMEPA1-e isoform and characterized its biological functions in prostate cancer. The study found that the methylation of PMEPA1 gene promoter accounts for silencing of PMEPA1 in prostate cancer cells.
Researchers found that blocking androgen receptors can increase the density of prostate-specific membrane antigen (PSMA) sites on tumor surfaces, allowing for more targeted radiation therapy. This breakthrough could lead to more efficient treatment of advanced prostate cancer.
Researchers discovered that reactivating the PPP2R2A gene can slow or stop prostate cancer progression. The study found that patients with only one functional copy of the gene have shorter survival rates, and that reconstituting PP2A protein ultimately kills prostate cancer cells.
A study by researchers at the University of Texas M.D. Anderson Cancer Center identified a subset of immune macrophages that resist treatment with anti-PD-1 checkpoint blockade in glioblastoma patients. The team found that these CD73-expressing macrophages were associated with decreased survival, and that targeting them with combinatio...